Nuwellis Yönetim

Yönetim kriter kontrolleri 4/4

Nuwellis CEO'su Nestor Jaramillo, Jul2020 tarihinde atandı, in görev süresi 4.17 yıldır. in toplam yıllık tazminatı $ 606.60K olup, şirket hissesi ve opsiyonları dahil olmak üzere 69.3% maaş ve 30.7% ikramiyelerden oluşmaktadır. şirketin hisselerinin 0.006% ine doğrudan sahiptir ve bu hisseler € 136.26 değerindedir. Yönetim ekibinin ve yönetim kurulunun ortalama görev süresi sırasıyla 3.3 yıl ve 4.3 yıldır.

Anahtar bilgiler

Nestor Jaramillo

İcra Kurulu Başkanı

US$606.6k

Toplam tazminat

CEO maaş yüzdesi	69.3%
CEO görev süresi	4.2yrs
CEO sahipliği	0.006%
Yönetim ortalama görev süresi	3.3yrs
Yönetim Kurulu ortalama görev süresi	4.3yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Nestor Jaramillo'un ücretlendirmesi Nuwellis'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Jun 30 2024	n/a	n/a	-US$23m
Mar 31 2024	n/a	n/a	-US$20m
Dec 31 2023	US$607k	US$421k	-US$23m
Sep 30 2023	n/a	n/a	-US$17m
Jun 30 2023	n/a	n/a	-US$17m
Mar 31 2023	n/a	n/a	-US$17m
Dec 31 2022	US$715k	US$412k	-US$15m
Sep 30 2022	n/a	n/a	-US$17m
Jun 30 2022	n/a	n/a	-US$18m
Mar 31 2022	n/a	n/a	-US$19m
Dec 31 2021	US$1m	US$384k	-US$20m
Sep 30 2021	n/a	n/a	-US$18m
Jun 30 2021	n/a	n/a	-US$17m
Mar 31 2021	n/a	n/a	-US$17m
Dec 31 2020	US$481k	US$343k	-US$18m
Sep 30 2020	n/a	n/a	-US$19m
Jun 30 2020	n/a	n/a	-US$19m
Mar 31 2020	n/a	n/a	-US$20m
Dec 31 2019	US$639k	US$209k	-US$23m

Tazminat ve Piyasa: Nestor 'ın toplam tazminatı ($USD 606.60K ) German pazarındaki benzer büyüklükteki şirketler için ortalamadır ($USD 471.14K ).

Tazminat ve Kazançlar: Nestor 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Nestor Jaramillo (67 yo)

4.2yrs

Görev süresi

US$606,603

Tazminat

Mr. Nestor Jaramillo, Jr. has been President of Nuwellis, Inc. (formerly known as CHF Solutions, Inc.) since July 1, 2020 and has been its Chief Executive Officer and Director since January 16, 2021 and se...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nestor Jaramillo	President	4.2yrs	US$606.60k	0.0063% € 136.3
Robert Scott	Chief Financial Officer	less than a year	US$291.41k	0% € 0
Neil Ayotte	Senior VP	3.3yrs	US$406.49k	0% € 0
John Kowalczyk	Senior Vice President of Sales & Marketing	2.7yrs	Veri yok	Veri yok
Sandra Eayrs	Chief Human Resources Officer	9.7yrs	Veri yok	Veri yok
John Jefferies	Chief Medical Officer & Member of Medical Advisory Board	1.7yrs	Veri yok	Veri yok
Paul Wotta	Corporate Controller	12.8yrs	Veri yok	Veri yok

3.3yrs

Ortalama Görev Süresi

64yo

Ortalama Yaş

Deneyimli Yönetim: 22S 'un yönetim ekibi deneyimli olarak değerlendirilmektedir (ortalama görev süresi 3.3 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Nestor Jaramillo	President	3.7yrs	US$606.60k	0.0063% € 136.3
John Jefferies	Chief Medical Officer & Member of Medical Advisory Board	no data	Veri yok	Veri yok
John Erb	Chairman of the Board	12yrs	US$65.86k	0% € 0
Gregory Waller	Independent Director	13.1yrs	US$68.86k	0% € 0
Michael McCormick	Lead Independent Director	1.3yrs	US$25.66k	0% € 0
Maria Costanzo	Independent Director & Member of Medical Advisory Board	5yrs	US$53.79k	Veri yok
Archelle Georgiou	Independent Director	less than a year	Veri yok	0% € 0
Steven Coca	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Daniel Beckles	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Maria DeVita	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Aroti Hegde	Member of Medical Advisory Board	no data	Veri yok	Veri yok
Sitaramesh Emani	Member of Medical Advisory Board	no data	Veri yok	Veri yok

4.3yrs

Ortalama Görev Süresi

68yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: 22S 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 4.3 yıldır).

Nuwellis Yönetim

Yönetim kriter kontrolleri 4/4

Anahtar bilgiler

Son yönetim güncellemeleri

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

Nuwellis, Inc. Announces Board Changes

Nuwellis Appoints John Jefferies as Chief Medical Officer

Recent updates

Nuwellis Provides Revenue Guidance for Third Quarter Ended September 30, 2024

Nuwellis, Inc. to Report Q3, 2024 Results on Nov 11, 2024

Seastar Medical Holding Corporation Enters into Confidential Settlement Agreement and Release with Nuwellis

Nuwellis, Inc. has completed a Follow-on Equity Offering in the amount of $0.891783 million.

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $0.916782 million.

Nasdaq Panel Grants Nuwellis Continued Listing on the Nasdaq Stock Market, Subject to Conditions

Nuwellis Announces First Pediatric Patient Treated in A Commercial Setting with Seastar Medical's Quelimune Therapy At Cincinnati Children's

Nuwellis, Inc. has filed a Follow-on Equity Offering in the amount of $1.990002 million.

Nuwellis, Inc. to Report Q2, 2024 Results on Aug 13, 2024

Nuwellis Marks First Commercial Sale of Quelimune Therapy to Cincinnati Children's

Nuwellis, Inc. Announces New Clinical Evidence Demonstrating the Efficacy of its Aquadex® System to be Presented at HFSA 2024 Conference

Nuwellis Receives Non-Compliance Letter from Nasdaq Regarding Minimum Stockholders' Equity Requirement

First quarter 2024 earnings released: US$0.78 loss per share (vs US$5.76 loss in 1Q 2023)

Nuwellis, Inc. Receives USPTO Notice of Patent Allowance for Innovative Pediatric CRRT Technology

Nuwellis, Inc. to Report Q1, 2024 Results on May 07, 2024

Nuwellis, Inc. Announces Launch of Ultrafiltration Therapy Using Aquadex Smartflow® System at Henry Ford Health

Nuwellis, Inc. Announces Results from Two New Clinical Data Analyses from the AVOID-HF Trial, Which Demonstrate the Benefits of its Aquadex System in Reducing Heart Failure Readmissions at 30 Days

Full year 2023 earnings released: US$11.52 loss per share (vs US$83.48 loss in FY 2022)

Nuwellis, Inc. to Report Q4, 2023 Results on Mar 05, 2024

Nuwellis, Inc. Receives FDA Clearance for an Additional Dual Lumen Extended Length Peripheral Catheter

Nuwellis Receives Non-Compliance Notice from Nasdaq

Nuwellis, Inc. Announces New Real-World Data Highlight the Clinical Benefits of Ultrafiltration Therapy with Hematocrit Monitoring Foriatric Patients

Third quarter 2023 earnings released: US$1.81 loss per share (vs US$36.72 loss in 3Q 2022)

New major risk - Revenue and earnings growth

Less than half of directors are independent

Nuwellis, Inc. Announces Board of Directors Transition

Nuwellis, Inc. to Report Q3, 2023 Results on Nov 07, 2023

Nuwellis, Inc. has completed a Composite Units Offering in the amount of $2.25 million.

Nuwellis Provides Regulatory Update on Seastar Medical's Selective Cytopheretic Device Use in Pediatric Acute Kidney Injury Under A Humanitarian Device Exemption

Nuwellis, Inc. Appoints Robert B. Scott as Chief Financial Officer, Effective September 2, 2023

Second quarter 2023 earnings released: US$3.65 loss per share (vs US$40.67 loss in 2Q 2022)

Nuwellis, Inc. to Report Q2, 2023 Results on Aug 08, 2023

New major risk - Revenue and earnings growth

Nuwellis, Inc. Announces the Appointment of Mike Mccormick to its Board of Directors

First quarter 2023 earnings released: US$5.76 loss per share (vs US$42.45 loss in 1Q 2022)

Full year 2022 earnings released: US$83.48 loss per share (vs US$287 loss in FY 2021)

Nuwellis, Inc. to Report Q4, 2022 Results on Feb 28, 2023

Nuwellis, Inc. Announces Board Changes

Nuwellis, Inc. Provides Preliminary Revenue Guidance for the Fourth Quarter and Full Year Ended December 31, 2022

Nuwellis Appoints John Jefferies as Chief Medical Officer

Nuwellis Announces Compliance with Nasdaq Listing Requirements

Nuwellis, Inc. Receives 180-Day Extension to Meet Nasdaq Minimum Bid Price Requirement

Insufficient new directors

Third quarter 2022 earnings released: US$0.37 loss per share (vs US$0.74 loss in 3Q 2021)

Nuwellis, Inc. Announces Peer Reviewed Data Demonstrating 71% Survival with Kidney Replacement Therapy Using A Modified Aquadex in Low-Birth-Weight Preterm Neonates

Insufficient new directors

Nuwellis, Inc. to Report Q3, 2022 Results on Nov 08, 2022

Nuwellis, Inc. Provides Product Revenue Guidance for the Three Months Ended September 30, 2022

Nuwellis Announces Data Demonstrating Statistically Superior Clinical Benefit of Aquadex Therapy in Reducing Heart Failure Events and Mortality At the 2022 Hfsa Meeting

Insufficient new directors

Nuwellis, Inc. Announces the Activation of New Sites for Its Pivotal REVERSE-HF Trial

Nuwellis, Inc. Announces Executive Changes

Nuwellis, Inc. Announces New Clinical Data Demonstrating 100% Survival at 30 Days Following Use of Ultrafiltration in High-Risk Postoperative Coronary Artery Bypass Grafting (CABG) Patients

Nuwellis, Inc. Announces U.S. Patent and Trademark Office Awards Patent for Innovative Pediatric Technology

Second quarter 2022 earnings released: US$0.41 loss per share (vs US$0.72 loss in 2Q 2021)

Nuwellis, Inc Announces the Submission of the AVOID-HF Clinical Analysis as a Late Breaking Clinical Trial at HFSA

Nuwellis, Inc. to Report Q2, 2022 Results on Aug 09, 2022

Nuwellis, Inc. Announces First Patient Enrolled in Its Pivotal Trial REVERSE-HF

Nuwellis Receives a Letter from the Listing Qualifications Department of Nasdaq Regarding Minimum Bid Price Requirement

First quarter 2022 earnings released: US$0.42 loss per share (vs US$1.25 loss in 1Q 2021)

Nuwellis, Inc. to Report Q1, 2022 Results on May 10, 2022

Nuwellis, Inc., Annual General Meeting, May 17, 2022

Full year 2021 earnings: EPS in line with expectations, revenues disappoint

Nuwellis, Inc. Initiates REVERSE-HF Study to Evaluate Ultrafiltration for Heart Failure Patients with Fluid Overload

Nuwellis, Inc. to Report Q4, 2021 Results on Mar 01, 2022

Nuwellis, Inc. Provides Revenue Guidance for the Full Year 2021

Nuwellis Provides More Children in Texas With Access to Its Unique Fluid Management Technology

CHF Solutions Submits Patent Application for New Peripheral Venous Access Technology for Ultrafiltration and CRRT Systems

Chf Solutions Expands Access to Ultrafiltration Therapy for Pediatric Patients in Puerto Rico